Commentary

Article

State of the Science Summit - Lung Cancer: Chaired by Kathryn F Mileham, MD, FACP, FASCO

In Partnership With:

State of the Science Summit - Lung Cancer: Chaired by Kathryn F Mileham, MD, FACP, FASCO.

State of the Science Summit - Lung Cancer: Chaired by Kathryn F Mileham, MD, FACP, FASCO

Speakers

  • Christopher Pallas, MD | Atrium Health Levine Cancer Institute
  • Daniel Haggstrom, MD | Atrium Health Levine Cancer Institute
  • Daniel Carrizosa, MD, MS | Atrium Health Levine Cancer Institute
  • John Heinzerling, MD | Atrium Health Levine Cancer Institute
  • Z. Luke Farmer, MD | Atrium Health Levine Cancer Institute

Topics

  • Perioperative Strategies in NSCLC
  • Targeting EGFR and ALK+ NSCLC
  • Emerging Targeted Therapies for NSCLC
  • Antibody-Drug Conjugates (ADC) in NSCLC
  • Community Clinical Scenarios: NSCLC
  • Recent Advances in Limited Stage SCLC

Interested in virtually attending an IPC event? Click here to register for an upcoming webinar.

Some of the episodes from our podcast, OncLive On Air, are focused on the interviews with faculty conducted at the State of the Science Summits. Click here to listen to our latest episodes!

Related Videos
Shirish M. Gadgeel, MD
Sanjay Popat, BSc, MBBS, FRCP, PhD, consultant medical oncologist, The Royal Marsden Hospital; professor, thoracic oncology, the Institute of Cancer Research
Nicolas Girard, MD, professor, respiratory medicine, Versailles Saint Quentin University; head, Curie-Montsouris Thorax Institute, chair, Medical Oncology Department, Institut Curie
T. Jeroen N. Hiltermann, MD, of University of Groningen
Benjamin Besse, MD, PhD, of Institute Gustave Roussy
Xiuning Le, MD, PhD, of The University of Texas MD Anderson Cancer Center
Natasha B. Leighl, MD, BSc, MMSc, of the Princess Margaret Cancer Centre
John V. Heymach, MD, PhD, chair, Thoracic/Head and Neck Medical Oncology, and the David Bruton Endowed Chair in Cancer Research, The University of Texas MD Anderson Cancer Center
Yi-Long Wu, MD, PhD, of the Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University
Triparna Sen, PhD, of Icahn School of Medicine at Mount Sinai
Related Content
Marjorie Green, MD
September 17th 2024

Patritumab Deruxtecan Meets PFS End Point in Pretreated EGFR-Mutant NSCLC

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

Jonathan D. Spicer, MD, PhD, FRCS, of McGill University Health Centre
September 15th 2024

Perioperative Nivolumab Shows EFS Benefit vs Placebo in Resectable NSCLC

Narjust Florez, MD
September 5th 2024

Florez Focuses on Patient-Centered NSCLC Biomarker Testing Discussions

Fabrice Barlesi, MD, PhD, thoracic oncologist, Paris Saclay University and chief executive officer of Gustave Roussy Institute
September 14th 2024

Adagrasib Is Superior to Docetaxel in Pretreated KRAS G12C–Mutated NSCLC

Antonio Passaro, MD, PhD
September 14th 2024

Zipalertinib Demonstrates Safety, Disease Control in Heavily Pretreated EGFR Exon 20-Mutated NSCLC